Iodixanol and iopamidol are commonly used contrast agents in coronary angiography. We evaluated the nephrotoxic effects of both contrast media in relation to renal biomarkers. A total of 38 low-risk patients who underwent coronary angiography were enrolled. Patients were randomized to receive either low-osmolar nonionic monomer or isoosmolar nonionic dimer contrast medium. N-Acetyl-β-d-glucosaminidase (NAG), endothelin, blood urea nitrogen, and urine and serum creatinine (SCr) levels were measured before the procedure (T0), at 6 hours (T6), and at 1 year after the procedure. Plasma endothelin, urine NAG/creatinine, and SCr were higher; accordingly, the urine creatinine values were lower in both the groups when comparing T0 versus T6. The groups were similar with each other when comparing T0 and T6 values. Both the contrast agents may be safely used at a low volume for coronary angiography in low-risk patients. Endothelin and NAG are sensitive to acute renal changes in function. There is a need for further prospective investigations with more patients.
HeinrichMCHäberleLMüllerVBautzWUderM. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009;250(1):68–86.
2.
PerrinTDescombesECookS. Contrast-induced nephropathy in invasive cardiology. Swiss Med Wkly. 2012;142:w13608.
3.
GuptaRBangTJ. Prevention of contrast-induced nephropathy (CIN) in interventional radiology practice. Semin Intervent Radiol. 2010;27(4):348–359.
4.
ThomsonVSNarayananKSinghJC. Contrast induced nephropathy in urology. Indian J Urol. 2009;25(4):437–445.
5.
HuangSSHuangPHWuTCChenJWLinSJ. Association of serum bilirubin with contrast-induced nephropathy and future cardiovascular events in patients undergoing coronary intervention. PLoS One. 2012;7(8):e42594.
6.
FungJWSzetoCCYuCM. Preventing contrast nephropathy in catheter laboratory. Heart. 2007;93(6):654–655.
7.
ItohYYanoTSendoTOishiR. Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media. J Pharmacol Sci. 2005;97(4):473–488.
8.
AnaratADumanNNoyanNKibarMAnaratR. The role of endothelin in radiocontrast nephropathy. Int Urol Nephrol. 1997;29(5):609–613.
9.
RenLJiJFangY. Assessment of urinary N-acetyl-β-glucosaminidase as an early marker of contrast-induced nephropathy. J Int Med Res. 2011;39(2):647–653.
10.
ChertowGMBurdickEHonourMBonventreJVBatesDW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–3370.
11.
BarrettBJKatzbergRWThomsenHS. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41(11):815–821.
12.
ZhangYWangJYangX. The serial effect of iodinated contrast media on renal hemodynamics and oxygenation as evaluated by ASL and BOLD MRI. Contrast Media Mol Imaging. 2012;7(4):418–425.
13.
IdeéJMLancelotEBerthommierCCouturier-GoulasVVazinVCorotC. Effects of non-ionic monomeric and dimeric iodinated contrast media on renal and systemic haemodynamics in rats. Fundam Clin Pharmacol. 2000;14(1):11–18.
14.
LockEA. Sensitive and early markers of renal injury: where are we and what is the way forward?Toxicol Sci. 2010;116(1):1–4.
15.
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group, KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138.
16.
ParaskevasKIGiannoukasADKotsikorisIMikhailidisDP. Contrast-induced nephropathy and the vascular patient. Angiology. 2010;61(8):721–723.
17.
HussainNAl OtaibiTNampooryMRN. Contrast-media nephropathy: in depth review. Saudi J Kidney Dis Transpl. 2008;19(2):174–182.
18.
HanWKWaikarSSJohnsonA. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 2008;73(7):863–869.
19.
FeldkampTBaumgartDElsnerM. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol. 2006;66(5):322–330.
20.
WaringWSMoonieA. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011;49(8):720–728.
21.
ShakerOGEl-ShehabyAEl-KhatibM. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. 2010;61(8):731–736.
22.
McCulloughPAAdamABeckerCR. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):5K–13K.
23.
FreemanRVO’DunnellMShareD. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90(10):1068–1073.
24.
SolomonRJMehranRNatarajanMK. Contrast-induced nephropathy and long-term adverse effects: cause and effect?Clin J Am Soc Nephrol. 2009;4(7):1162–1169.
25.
NguyenSASuranyiPRavenelJG. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology. 2008;248(1):97–105.
26.
ClarkBAKimDEpsteinFH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis. 1997;30(1):82–86.
27.
OzhanHErdenIOrduS. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 2010;61(7):711–714.
28.
SadatUWalshSRNordenAGGillardJHBoyleJR. Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology. 2011;62(3):225–230.
29.
OzcanEEGuneriSAkyildizB. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy: a comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007;154(3):539–544.
